Thomas P. Fondy is a professor in Department of Biology of Syracuse University, New York United States. He specializes in 1. Evaluation of cytoskeletal-directed anti-neoplastic agents, rapamycin, and cholesterol-altering agents in combination with Low-frequency Ultrasound against neoplastic and normal cells in cell culture and in mouse models of cancer. 2. Treatment-induced cell-enlargement and multinucleation of neoplastic human cell lines in culture, as a potential approach to the selective physical destruction of neoplastic cells based on cell size, nucelar and DNA-content, and cytoskeletal and membrane structure. 3. Pulsed Low-Frequency Ultra-sound in the Preferential Physical Destruction of Neoplastic Cells in the presence of normal blood cells in Cell Culture and in Pre-clinical Animal Models 4. Microfilament-directed, Microtubule-directed, and Intermediate filament-directed agents in the chemotherapy of cancers directed to cytoskeletal abnormalities in cancers. 5. Use of In Vivo mouse models for evaluation of approaches to the selective physical destruction leukemia cells and therapeutic management of cancers by whole-body chemotherapy, immunotherapy, and ultra-sonic treatment.

Physico-chemotherapy of leukemia in cell culture, actin microfilament in cell signaling, cytokinesis as a key target in cancer therapy.